Logo

Merck Reports Result of Keytruda (pembrolizumab) in P-III KEYNOTE-048 Study as a 1L Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Share this

Merck Reports Result of Keytruda (pembrolizumab) in P-III KEYNOTE-048 Study as a 1L Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Shots:

  • The P-III KEYNOTE-048 study results involves assessing of Keytruda + CT (carboplatin/cisplatin + 5-FU) and Keytruda as monothx. vs EXTREME regimen in 882 patients with recurrent or metastatic HNSCC- whose tumor expressed CPS≥20 & CPS ≥1- presented at ASCO 2019
  • The P-III KEYNOTE-048 study results: @ CPS≥20 & CPS ≥1 for combination- 40% & 35% reduction in death; OS (14.7 & 13.6 vs 11 & 10.4 mos.); ORR (42.9% & 36.4% vs 38.2% & 35.7%); mDOR (7.1 & 6.7 vs 4.2 & 4.3 mos.); for monthx- OS (11.5 vs 10.7mos.); ORR (16.9% vs 36.0%); mDOR (22.6 vs 4.5mos.) respectively
  • Keytruda is an anti PD-1 therapy- inhibits the interaction of PD-1 and its ligands- PD-L1 and PD-L2 by activating T-lymphocytes- currently evaluating in 1000+ clinical studies for multiple cancers and has received FDA’s PR to sBLA with its expected PDUFA date on Jun 10- 2019

Ref: Merck | Image: Merck        

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions